Brad Fremming, MD

Assistant Professor

  • 105 Citations
  • 3 h-Index
20052008
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Brad Fremming is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

rimonabant Medicine & Life Sciences
Obesity Medicine & Life Sciences
Cannabinoid Receptor Antagonists Medicine & Life Sciences
Piperidines Medicine & Life Sciences
Pyrazoles Medicine & Life Sciences
Cannabinoid Receptor CB1 Medicine & Life Sciences
Cannabinoid Receptors Medicine & Life Sciences
Dyslipidemias Medicine & Life Sciences

Research Output 2005 2008

  • 105 Citations
  • 3 h-Index
  • 2 Review article
  • 1 Letter

Taranabant, a novel cannabinoid type 1 receptor inverse agonist

Fremming, B. A. & Boyd, S. T., Oct 7 2008, In : Current Opinion in Investigational Drugs. 9, 10, p. 1116-1129 14 p.

Research output: Contribution to journalReview article

Cannabinoid Receptors
Obesity
Tobacco Use Disorder
Smoking Cessation
Tobacco Products
3 Citations (Scopus)

Update on rimonabant - A selective cannabinoid CB1 antagonist [1]

Boyd, S. T. & Fremming, B. A., May 1 2006, In : Annals of Pharmacotherapy. 40, 5, 1 p.

Research output: Contribution to journalLetter

rimonabant
Piperidines
Pyrazoles
Cannabinoid Receptor Antagonists
Cannabinoid Receptor CB1
91 Citations (Scopus)

Rimonabant - A selective CB1 antagonist

Boyd, S. T. & Fremming, B. A., Apr 1 2005, In : Annals of Pharmacotherapy. 39, 4, p. 684-690 7 p.

Research output: Contribution to journalReview article

rimonabant
Smoking Cessation
Cannabinoid Receptor Antagonists
Obesity